[Plasma Derivatives] Sero - Tet

▪Solvent/Detergent treated and Nanofiltered ▪For intravenous use only ▪Plasma from healthy donors  

 ✔ Alyglo : Human Intravenous immunoglobulin 10%
 - U.S. Approval in 2023
 - Successfully launching in 2024

 ✔ I.V.-Globulin SN inj. : Human intravenous Immunoglobulin 5%, 10%
 - A dominant leader of Korea since 1970
 - 611 mil. liters of IVIG distributed worldwide 

▪A 20% solution of human albumin prepared with a cold ethanol fractionation method from plasma from healthy donors

▪High concentrate of human anti-haemophilic factor VIII prepared from pooled plasma of healthy donors

▪Live attenuated varicella vaccine
- WHO-prequalified
- World's 1st Antibiotic-free varicella vaccine

▪Seasonal influenza vaccine
- WHO-prequalified
- Largest flu vaccine supplier to PAHO & UNICEF

▪World's 2nd ERT for MPS II

▪World's 1st ERT for Neuronopathic MPS II

Assessment of Immunogenicity and Safety of the Live Attenuated Varicella Vaccine (BARYCELA) in Adolescents and Adults was presented in 19th Vaccine Congress

GCBP Hunterase L.I.N.K. Day of the year. Doctors from Paraguay, Chile, Peru, Russia, Algeria, Malaysia, and South Korea came together to share valuable insights

Core Products of GC Biopharma

Brochure of Green Cross 

GC Biopharma Company Presentation 

E-Catalog of GC Biopharma

Core product of GC Biopharma

GCBP offers a comprehensive, end-to-end mRNA CDMO service — covering codon-optimized sequence design, pDNA production, IVT mRNA synthesis, LNP formulation, aseptic fill & finish, and full analytical & regulatory support. With proprietary technologies and flexible manufacturing infrastructure, we enable fast and reliable development of mRNA vaccines and therapeutics.

FDA approved, Immune globuline Intravenous, 10% liquidPure Ig with extra purification step

A sterile solution of hepatitis B immune globulin prepared by cold ethanol fractionation method, which had high titer of antibody to hepatitis B surface antigen and found negative for HBsAg, anti-HIV and anti-HCV